(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number
WO 2004/105763 A3

(51) International Patent Classification[7]: A61K 31/506, 31/498, 31/517, 31/404, 31/42, 31/437, 31/47, 31/519, 38/12, 38/19, A61P 3/10

(21) International Application Number:
PCT/EP2004/005679

(22) International Filing Date: 26 May 2004 (26.05.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0312086.2	27 May 2003 (27.05.2003)	GB
0402682.9	6 February 2004 (06.02.2004)	GB

(71) Applicants and
(72) Inventors: **HÄGERKVIST, Robert, Per** [SE/SE]; Höganäsgatan 7B, S-753 30 Uppsala (SE). **WELSH, Nils, Richard** [US/SE]; Luthagsesplanaden 14, S-752 25 Uppsala (SE).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
2 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF TYROSINE KINASE INHIBITOR TO TREAT DIABETES

(57) Abstract: The invention relates to the use of a c-Abl-. PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, Bis (1H-2-indolyl)-1-methanones, AG1295, CT52923, RP-1776; GFB-111; pyrrolo[3,4-c]-beta-carboline-diones, SU 102, AG1296, RPR101511A, CDP 860, Zvegf3, CP673451, PD 170262, KI 6783, KN 1022, AG 13736, CHIR 258, MLN 518, SU 11248, Leflunomide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.

WO 2004/105763 A3